Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Clinica Universidad de Navarra, Universidad de Navarra
Canadian Cancer Trials Group
Fudan University
SWOG Cancer Research Network
Tempus AI